Stock Market Reviews

STOK (Stoke Therapeutics, Inc.) News

Get the latest news, insights, and market updates on STOK (Stoke Therapeutics, Inc.). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Stoke Therapeutics (NASDAQ:STOK) shareholders are still up 246% over 3 years despite pulling back 4.8% in the past week
  The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But in contrast you can...
  Dec 29, 2025 - $STOK
• Biotech Leader Stoke Therapeutics Offers Multiple Entries As Revenue Surges 117%
  Biotech leader Stoke stock is running up toward a new buy point. The company's revenue surged 117% in Q3.
  Dec 16, 2025 - $STOK
• Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
  BEDFORD, Mass., December 16, 2025--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today announced that, effective on December 15, 2025, it granted stock options to purchase an aggregate of 131,280 shares of common stock to e
  Dec 16, 2025 - $STOK
• Stoke Therapeutics' Chief Medical Officer Sold Over 5,000 Shares in the Company. Should Shareholders Sell?
  This biotech targeting rare genetic diseases reported a notable insider sale following a year of rapid share price gains.
  Dec 11, 2025 - $STOK
• Is New Neurology Data And Partnerships Altering The Investment Case For Biogen (BIIB)?
  In late November and early December 2025, Biogen and its partners Eisai, Stoke Therapeutics and Dayra Therapeutics reported new clinical data and collaborations spanning Alzheimer’s disease, Dravet syndrome and oral macrocyclic peptide research, including positive updates on lecanemab’s subcutaneous formulation and zorevunersen’s long-term effects. The latest findings suggest Biogen is deepening its presence in high-need neurological conditions with therapies that aim not only to relieve...
  Dec 7, 2025 - $STOK
• Biogen and Stoke Therapeutics Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting
  —Long-term Phase 1/2a and open label extension (OLE) data for zorevunersen on top of standard of care anti-seizure medicines (ASMs) demonstrate durable seizure reductions, including increases in seizure-free days, in addition to improvements in cognition, behavior and quality of life— —Propensity score weighted analysis comparing the effects of zorevunersen to natural history showed reductions in seizures and improvements in cognition and behavior with dose levels and timepoints similar to and c
  Dec 5, 2025 - $STOK
• Stoke Therapeutics and Biogen Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting
  BEDFORD, Mass. & CAMBRIDGE, Mass., December 05, 2025--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine, and Biogen Inc. (Nasdaq: BIIB) today announced data presentations that further support the potential of zorevunersen, an investigational antisense oligonucleotide, as a disease-modifying medicine for Dravet syndrome. These data were presented at the 2025 American Epilepsy Society (AES
  Dec 5, 2025 - $STOK
• A Look at Stoke Therapeutics (STOK) Valuation After a 167% Year-to-Date Surge
  Stoke Therapeutics (STOK) shares have seen significant movement this year. Investors are watching closely as the company advances its genetic disease treatment pipeline and continues to collaborate with industry peers. See our latest analysis for Stoke Therapeutics. Stoke Therapeutics has captured attention with a remarkable year-to-date share price return of nearly 167 percent, fueled by clinical progress and new collaborations. This sharp upward momentum marks a turnaround from prior years,...
  Dec 2, 2025 - $STOK
• Biogen and Stoke Therapeutics Announce Presentations at the 2025 American Epilepsy Society Annual Meeting
  New analyses from the ongoing open label extension (OLE) studies and findings from electroencephalogram (EEG) assessments in patients with Dravet syndrome treated with zorevunersen support the potential for disease modificationCAMBRIDGE, Mass and BEDFORD, Mass., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine, today annou
  Dec 1, 2025 - $STOK
• Stoke Therapeutics and Biogen Announce Presentations at the 2025 American Epilepsy Society Annual Meeting
  BEDFORD, Mass. & CAMBRIDGE, Mass., December 01, 2025--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine, and Biogen Inc. (Nasdaq: BIIB) today announced data presentations from studies of zorevunersen at the 2025 American Epilepsy Society (AES) Annual Meeting, taking place December 5-9 in Atlanta, Georgia.
  Dec 1, 2025 - $STOK